How is response to combination ribavirin and propylene glycol (PEG)-interferon (IFN) therapy for hepatitis C (hep C) infection determined?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print
Answer

Response to therapy of HCV genotype 1 (ie, achievement of SVR) can be predicted by identifying the single nucleotide polymorphisms (SNPs) located in the region of interleukin (IL)-28B gene through genome-wide association studies (GWAS). Patients with the CC genotype of the IL-28B have a much more favorable response as compared to the CT or TT genotype (70% vs 25%-30%). Testing for IL-28B genotype is thus a useful tool in the management of patients with interferon and ribavirin combination therapy. [92]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!